Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27444155 | 0.98 | SRC (0.47) | SRCCES1HPGDCYP2D6HDAC3 | |
| Hydrochloric Acid SCHEMBL27461611 | 0.96 | SRC (0.45) | SRCCES1HPGDCYP2D6HDAC3 | |
| SCHEMBL22351001 | 0.88 | SRC (0.56) | SRCCES1CYP2D6HDAC3HDAC4 | |
| SCHEMBL28895362 | 0.83 | HDAC3 (0.39) | CES1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL28437637 | 0.81 | HDAC4 (0.45) | CES1HDAC4KMT2AMEN1 | |
| SCHEMBL1312762 | 0.81 | SRC (0.64) | SRCCES1HPGDCYP2D6HDAC3 | |
| SCHEMBL29256700 | 0.81 | SRC (0.48) | SRCCES1HPGDCYP2D6LMNA | |
| SCHEMBL8858902 | 0.80 | SRC (0.44) | SRCCES1HDAC4HDAC6LMNA | |
| SCHEMBL27542241 | 0.80 | UGT2B7 (0.46) | CYP2D6KMT2AMEN1 | |
| SCHEMBL11012611 | 0.79 | SRC (0.61) | SRCCES1HPGDCYP2D6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090242839-A1 | Gas-phase infiltration of phosphors into the pore system of inverse opals | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-01 | — | — | US | claimed |
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-7863446-B2 | Heterocycles | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-20100329998-A1 | NOVEL HETEROCYCLES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-12-30 | — | — | US | disclosed |
| EP-2245017-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2010-11-03 | — | — | EP | disclosed |
| US-20090242839-A1 | Gas-phase infiltration of phosphors into the pore system of inverse opals | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-01 | — | — | US | disclosed |
| WO-2009095773-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008148454-A1 | INVERSE OPALS ON THE BASIS OF LUMINESCENT MATERIALS | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | WO | disclosed |
| EP-1997158-A1 | GAS PHASE INFILTRATION OF LUMINOUS SUBSTANCES INTO THE PORE SYSTEM OF INVERSE OPALS | Merck Patent GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1973884-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2008-10-01 | — | — | EP | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| WO-2007107226-A1 | GAS PHASE INFILTRATION OF LUMINOUS SUBSTANCES INTO THE PORE SYSTEM OF INVERSE OPALS | MERCK PATENT GMBH (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007083182-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
| EP-0289390-B1 | PROCESS FOR ELIMINATING RADIOACTIVITY FROM EFFLUENTS BY LIQUID-LIQUID EXTRACTION | RHONE-POULENC CHIMIE (FR) | 1991-10-16 | — | — | EP | disclosed |
| US-5006254-A | Extraction with halogenated beta-diketone | RHONE-POULENC CHIMIE (FR) | 1991-04-09 | — | — | US | disclosed |
| EP-0289390-A1 | Process for eliminating radioactivity from effluents by liquid-liquid extraction | RHONE-POULENC CHIMIE (FR) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | SRC 4078/4885CES1 1016/4885HPGD 1596/4885 |
| US-20100329998-A1 | NOVEL HETEROCYCLES | UACA, GPR4, CASP4 | SRC 4271/4885CES1 935/4885HPGD 1535/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | SRC 3454/4885CES1 1529/4885HPGD 1924/4885 |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | UMPS, PNP, PDE4A | SRC 4145/4885CES1 959/4885HPGD 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.